Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 8705862.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The mdm2 oncogene encodes a 90-kilodalton nuclear phosphoprotein that binds and inactivates the p53 tumor suppressor protein. Here we report the observation of five alternatively spliced mdm2 gene transcripts in a range of human cancers and their absence in normal tissues. Transfection of NIH 3T3 cells with each of these forms gave foci of morphologically transformed cells. A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and bladder carcinomas. Four of the splice variants show loss of p53 binding, consistent with partial deletion of sequences encoding the p53 binding domain, but retain carboxyterminal zinc-finger domains. These observations suggest a reassessment of the transforming mechanisms of mdm2 and its relation to p53.
Medical subject headings
- 3T3 Cells
- Alternative Splicing
- Animals
- Base Sequence
- Cell Transformation, Neoplastic
- DNA Primers
- Disease Progression
- Female
- Humans
- Leukemia
- Leukemia/metabolism
- Mice
- Molecular Sequence Data
- Neoplasm Proteins
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- Nuclear Proteins
- Ovarian Neoplasms
- Ovarian Neoplasms/metabolism
- Ovarian Neoplasms/pathology
- Protein Binding
- Proto-Oncogene Proteins
- Proto-Oncogene Proteins/genetics
- Proto-Oncogene Proteins/metabolism
- Proto-Oncogene Proteins c-mdm2
- RNA
- RNA/metabolism
- Transformation, Genetic
- Tumor Suppressor Protein p53
- Tumor Suppressor Protein p53/metabolism
- Urinary Bladder Neoplasms
- Urinary Bladder Neoplasms/metabolism
- Urinary Bladder Neoplasms/pathology